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This article reviews experimental and clinical data on the use of magnesium as a neuroprotective agent in various
conditions of cerebral ischemia. Whereas magnesium has shown neuroprotective properties in animal models of
global and focal cerebral ischemia, this effect could not be reproduced in a large human stroke trial. These
conflicting results may be explained by the timing of treatment. While treatment can be started before or early
after ischemia in experimental studies, there is an inevitable delay of treatment in human stroke. Magnesium
administration to women at risk for preterm birth has been investigated in several randomized controlled trials and
was found to reduce the risk of neurological deficits for the premature infant. Postnatal administration of
magnesium to babies after perinatal asphyxia has been studied in a number of controlled clinical trials. The results
are promising but the trials have, so far, been underpowered. In aneurysmal subarachnoid hemorrhage (SAH),
cerebral ischemia arises with the onset of delayed cerebral vasospasm several days after aneurysm rupture. Similar
to perinatal asphyxia in impending preterm delivery, treatment can be started prior to ischemia. The results of
clinical trials are conflicting. Several clinical trials did not show an additive effect of magnesium with nimodipine,
another calcium antagonist which is routinely administered to SAH patients in many centers. Other trials found a
protective effect after magnesium therapy. Thus, it may still be a promising substance in the treatment of
secondary cerebral ischemia after aneurysmal SAH. Future prospects of magnesium therapy are discussed.Pathophysiology and molecular effects
The interruption of cerebral blood flow (CBF) is
followed by a complex pathophysiological cascade which
ultimately results in ischemic cell death. ATP-depletion
and ischemic depolarization lead to excessive cellular
calcium-entry. Under physiological conditions, calcium
is an important second messenger whereas excessive cal-
cium is toxic and induces mechanisms of cell destruc-
tion. Depending on the kind and severity of ischemia,
tissue necrosis and/or apoptosis are the ultimate conse-
quences [1]. Since the importance of calcium in ischemic
cell death had been discovered, calcium antagonists have
come into the focus of ischemic neuroprotection [2].
Magnesium has been called “nature’s physiologic cal-
cium blocker” as it is a physiological mineral and inter-
feres with calcium in a variety of ways [3]. The bivalent
magnesium cation can compete with calcium ions for* Correspondence: Westermaier.T@nch.uni-wuerzburg.de
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distribution, and reproduction in any mediumreceptor binding or passage through ion channels. It di-
lates blood vessels by competitive inhibition of voltage-
dependent calcium channels in vascular smooth muscle
cells [4], improves rheological functions by inihibiton of
platelet aggregation [5,6], and increases the deformability
of red blood cells [7]. Under experimental conditions, it
prevents cellular calcium influx and excitatory amino acid
release in neurons by blockade of N-type and L-type cal-
cium channels [8], prevents cellular calcium entry through
NMDA-receptor channels [9], reduces calcium-induced
mitochondrial dysfunction [10] and preserves cellular en-
ergy metabolism [11]. By these mechanisms, magnesium
may inhibit or delay ischemic cell death during and after
cerebral ischemic events.Physiological concentrations and side effects
In human serum, the physiological magnesium concentra-
tion is 0.7 – 1.1 mmol/l [12]. Magnesium is almost com-
pletely renally excreted. Oral intake may result in diarrhea
but does not markedly increase serum concentrationsntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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magnesium has been used for a long time in obstetrics for
the treatment of eclampsia and in cardiology for the treat-
ment of supraventricular tachycardia. Therefore, side effects
are well-defined. During magnesium treatment, hypocalce-
mia develops (Figure 1). With increasing serum concentra-
tions, hypotension and bradycardia occur and tendon
reflexes disappear. Serum concentrations over 6 mmol/l can
result in coma, respiratory insufficiency and cardiac arrest.
In patients with renal failure, magnesium may quickly accu-
mulate and result in hazardous side effects.
Low blood pressure is a risk factor for aggravation of
ischemic damage in states of cerebral ischemia reducing
collateral flow in the ischemic penumbra. Therefore,
magnesium doses must be kept low enough to ensure
stable blood pressure if it is administered for the pur-
pose of neuroprotection. In an experimental study of
temporary middle cerebral artery occlusion (MCAO) in
rats, serum concentrations of 2.0 – 2.5 mmol/l showed
the highest neuroprotective effect [13]. In higher doses,
the cardiodepressive effect seemed to limit the extent of
neuroprotection. In the clinical use in stroke and SAH,
reports about side effects are diverse. Most authors did
not find significant side effects apart from hypocalcemia,
occasional flushing or a slight tendency to bradycardia
[14-20], others reported significant hypotension and car-
diorespiratory depression in spite of close surveillance of
serum levels [21]. Co-treatment with other pharmaceut-
ics with a antihypertensive potential may be a possible
factor. The doses that are required to maintain certain
target levels vary widely and depend on renal excretion
[19]. Serum electrolyte concentrations are to be followed
frequently with consequent adaptation of infusion rates.
With a mean of 1.27 ± 0.15 mmol/l, physiologicalFigure 1 Serum concentrations of magnesium and calcium.
After the start of intravenous magnesium administration, a
significant decrease of the serum calcium concentration is observed.cerebrospinal fluid (CSF) concentrations are higher than
serum concentrations suggesting an active transport
through the blood–brain-barrier and blood-CSF-barrier.
However, CSF concentrations increase only moderately
even after several days of high-dose administration (1.50 ±
0.16 mmol/l at serum levels of 2.14 ± 0.21) indicating a
saturation of transport capacity [19] (Figure 2).
Experimental data
The use of magnesium as a neuroprotective agent has
been examined in various experimental models of cerebral
ischemia with rather conflicting results. This may be
explained by the variety of experimental models, the wide
range of target parameters, and the different dosages, tim-
ing and routes of administration. Experimental data was
collected by a Medline search for “magnesium”, “experi-
mental” and “cerebral ischemia” or “cerebral hypoxia”.
Global ischemia
Blair et al. did not find a reduction of hippocampal dam-
age by a 5 mmol/kg intravenous bolus of magnesium chlor-
ide (MgCl2) immediately before 10 minutes of bilateral
carotid occlusion in rats. Regarding the well-known
concentration-related spectrum of side effects, it is re-
markable that the authors did not observe any major side
effects – especially regarding cardiovascular parameters -
although the single intravenous bolus injection led to a
tenfold elevation of plasma levels 10-fold [12,22]. The ani-
mals’ heart-rate, the most sensitive parameter during mag-
nesium treatment, however, was not measured so that a
cardiodepressive effect cannot be finally excluded [19].
Studies with slower resorption of magnesium, in con-
trast, showed neuroprotective effects in global ischemia.
The subcutaneous administration of the same amountFigure 2 Even after prolonged intravenous magnesium
administration, CSF concentrations remain distinctly lower than
serum concentrations indicating a saturation of active
transport via the blood brain barrier and blood-CSF-barrier.
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before a 15-minute period of forebrain ischemia in rats
resulted in a 24% and 39% reduction of cell damage in
the hippocampal CA1- and CA3-area, respectively
[23]. Zhou et al. found a 50% reduction of hippocam-
pal damage by an intraperitoneal administration of 16
mmol/kg MgSO4 30 minutes prior to 10 minutes of
bilateral carotid artery occlusion [24]. However, neither
body nor brain temperature were measured and regu-
lated in these studies. In a series of studies using 8 mi-
nutes of bilateral carotid occlusion in rats, Zhu and
coworkers found that a postischemic temperature drop
could be the decisive factor for the neuroprotective
effect of magnesium. When animals were kept strictly
normothermic, magnesium did not reduce hippocampal
damage. If body temperature was mildly reduced, hippo-
campal damage was significantly reduced after magnesium
treatment compared to hypothermic controls [25,26].
Permanent focal ischemia
Several groups investigated the protective efficacy in stud-
ies of permanent focal ischemia [27-30]. Apart from Roffe
et al. [30], all authors reported reduced infarct volumes. In
all of these studies, magnesium was administered either
before or shortly after the onset of permanent middle
cerebral artery occlusion (MCAO). Yang et al. evaluated
the effect of magnesium administered 2, 6 or 8 hours after
permanent MCAO. While the survival rate improved only
in the 2-hour group, infarct volume decreased in the 2-
and 6 hour groups and neurological outcome improved in
all treatment groups [31]. This finding gave rise to the ex-
pectation that even delayed magnesium treatment might
be effective in stroke patients.Temporary focal ischemia
In a rat model of 90 minutes of MCAO, Marinov et al.
found a nearly 60% reduction of infarct volume after
24 hours by a preischemic intraarterial bolus of 90 mg/kg
MgSO4. The authors concluded that this superior protect-
ive effect was due to the intraarterial route of administra-
tion [32]. However, this overwhelming neuroprotective
effect could not be reproduced in a direct comparison of
intraarterial and intravenous administration of the same
dose in the same model [33]. The infarct volume – assessed
after 7 days - was reduced by 25% compared to saline
treated animals in both the intraarteial and the intravenous
groups. The difference between assessment of infarct vol-
ume after 1 day and after 7 days rather suggests that the
neuroprotective effect of magnesium may, in part, be tem-
porary [33]. The results of the latter study were rather con-
sistent with previous results of the same group [34].
In most studies, the neuroprotective effect of magne-
sium in transient focal ischemia was moderate butreproducible. Magnesium has shown synergistic effects
with other substances like radical scavengers and immu-
nosuppressants, which makes it an interesting substance
for the development of combination therapies [27,34]. An
experimental dose-finding study in transient MCAO in
rats showed the highest neuroprotective effect in animals
treated by a continuous elevation of serum levels to 2.0 –
2.5 mmol/l. Higher levels led to a cardiodepressive effect,
probably limiting the neuroprotective efficacy [13].Hypoxia/Ischemia
Several authors have studied the neuroprotective potential
of magnesium in perinatal asphyxia in animal models. In
an study of hypoxia/ischemia, Spandou and coworkers
subjected newborn rats to permanent unilateral carotid
occlusion and 1 or 2 hours of hypoxia by reduction of the
inspired oxygen fraction to 8%. Treatment with 4 doses of
500 mg/kg MgSO4 resulted in a delay of energy depletion
and a reduction of hippocampal damage compared to sa-
line treated control animals [35]. Using the same species
and experimental model, Thordstein et al. reported a
neuroprotective effect of MgSO4 in combination with the
oxygen scavengers L-Methionine and Mannitol deter-
mined as a less pronounced reduction of hemispheric
weight than in placebo treated control anaimals [36].
In contrast, magnesium treatment did not show a
neuroprotective effect in a model of hypoxia/ischemia in
piglets [37,38], where the animals were subjected to tem-
porary bilateral carotid occlusion and a reduction of the
inspiratory oxygen fraction to 0.12 until the ratio of
phosphocratinine and inorganic phosphate, determined by
magnetic resonance spectroscopy, had fallen to zero. The
authors neither found a delay of energy depletion after
MgSO4 treatment (400 mg/kg after 1 hour of resuscitation
and 200 mg/kg after 24 and 48 hours) [38] nor a reduction
of brain tissue damage [37]. In a model of 60 minutes
of hypoxia without carotid ligation (inspiratory oxygen
fraction 5 – 7%), in contrast, treatment with a bolus of
600 mg/kg MgSO4 followed by an infusion of 300 mg/kg
through 1 hour of hypoxia did preserve cerebral energy
stores in newborn piglets [39].
Experimental models of permanent and transient focal
cerebral ischemia find their clinical counterparts in embolic
stroke, events of temporary ischemia during neurosurgical
operations or delayed vasospasm after subarachnoid
hemorrhage, respectively, models of hypoxia/ischemia in
the clinical situation of perinatal asphyxia. Thus, a series of
clinical studies has been performed during the last 15 years
evaluating the neuroprotective potential of magnesium after
embolic stroke, its ability to prevent ischemic deficits
in secondary vasospasm after aneurysmal SAH and its
potential to ameliorate ischemic/hypoxic damage after peri-
natal asphyxia.
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Clinical data was collected by a MEDLINE-search for
“magnesium”, “clinical trial” and “stroke”, “subarachnoid
hemorrhage” or “asphyxia”.
Stroke
Promising results in experimental studies have raised high
expectations that magnesium might be a valuable drug for
the treatment of stroke patients. In 1984, a first clinical trial
was launched investigating the tolerability of magnesium in
human stroke [40]. In 1995, a randomized placebo-
controlled pilot study was published [41], in which 30 pa-
tients were treated by a bolus infusion of 8 mmol MgSO4
followed by a continuous infusion of 65 mmol over 24
hours in order to double the physiological serum concen-
trations. 30 patients served as a control group. In the mag-
nesium group, 30% of the patients were dead or disabled
compared to 40% in the control group. The dose regimen
had been chosen in accordance with previous studies on
myocardial infarction [42] and because serum levels of ap-
proximately 1.5 mmol/l had shown a neuroprotective effect
in experimental studies [32]. The initial bolus of 8 mmol,
however, did not markedly elevate serum magnesium levels
and target levels were only reached after 24 hours. A “dose
optimization study” was conducted in 25 patients prepar-
ing a large clinical trial. Target levels were most rapidly
reached by an initial bolus of 16 mmol MgSO4, still without
cardiovascular side effects [16]. The IMAGES-trial (Intra-
venous Magnesium Efficacy in Stroke Trial) was launched
in 1997 treating patients with ischemic stroke within 12
hours after the onset of symptoms and included 2598 pa-
tients [43]. After promising results of animal studies and
small pilot trials, this large multicenter trial did not show
an overall improvement of clinical outcome by magnesium
treatment. Only a subgroup of patients with lacunar stroke
profited from magnesium treatment [44] (Table 1).
It has been thoroughly discussed why the IMAGES
trial failed to reproduce the positive results gained in ex-
perimental studies. The sample size might have still been
too small or side effects might have been hazardous in
some patients masking a positive effect in the majority.
Moreover, the mean delay from the onset of clinical
symptoms to the beginning of treatment was 7 hours.
Since the efficacy of neuroprotective agents may de-
crease the longer their administration is delayed [31],
this issue is given consideration to by the currently
conducted FAST-MAG trial (“Field Administration of
Stroke Therapy – Magnesium”) in which patients are en-
rolled within the first 2 hours after the onset of stroke
symptoms [45]. One drawback of the IMAGES trial may
have been the lack of proper preclinical testing of the
dose-regimen and study-design before entering a large
multicenter trial. It was proposed that a target serum con-
centration twice as high as the physiological concentrationmay be the optimum treatment for stroke patients [16,41].
However, neither a preclinical dose-finding study using an
established experimental stroke model nor a clinical
(phase 2) dose-finding study had been conducted in ad-
vance to this large clinical trial.
Subarachnoid hemorrhage
Most cases of spontaneous SAH are caused by the rupture
of an intracranial aneurysm. Aneurysmal SAH is followed
by a sequence of different forms of cerebral ischemia: First,
global ischemia arises due to an elevation of intracranial
pressure (ICP). Starting immediately after SAH, a dissoci-
ation of cerebral perfusion pressure and CBF has been
found which enhances and prolongs the early perfusion
deficit after SAH. It is likely to be caused by an acute
vasoconstriction, a disseminated cerebrovascular reaction
[46,47]. Finally, delayed vasospasm of subarachnoid vessels
appears in a high percentage of SAH patients within the
first 2 weeks after SAH. Subarachnoid vessels become in-
creasingly spastic and cerebral blood flow (CBF) may fall
below ischemic thresholds [48]. This feared complication
affects 20 – 30% of SAH patients and may result in cere-
bral infarction, permanent morbidity or death. Delayed
cerebral vasospasm after SAH is self-limiting after several
days and, therefore, resembles a form of transient focal
ischemia. This bears the opportunity to undertake
neuroprotective measures prior to the onset of ischemia.
In an animal model of temporary MCAO, a dose-finding
study has demonstrated that the intra- and postischemic
maintainance of serum concentrations between 2.0 and 2.5
mmol/l offered the highest neuroprotection [13].
The potential role for a treatment with magnesium was
supported by the observation that hypomagnesemia is fre-
quently found in SAH patients and correlates with the
amount of blood in the subarachnoid space and with the
patient’s neurological condition at the time of hospital ad-
mission. Hypomagnesemia arising during the course of
treatment, in turn, correlates with the appearance of sec-
ondary neurological deficits and ischemic infarctions [49].
A series of clinical trials has been launched to assess the
ability to reduce secondary neurological deficits after SAH
(Table 2).
Luo and coworkers compared treatment with 100 – 200
mmol MgSO4 to a control group without giving other
calcium antagonists. The authors reported a reduced inci-
dence of secondary brain infarction and clinical deterior-
ation [50]. In a randomized study, Veyna and colleagues
raised serum magnesium levels to 1.7 – 2.3 mmol/l for 10
days in 20 SAH patients, reported no significant side effects
and a non-significant reduction of delayed vasospasm and
improvement of clinical outcome compared to 20 control
patients [18].
Chia and colleagues compared 23 SAH patients with
historical controls. Magnesium serum concentrations
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found a significant reduction of angiographic vaso-
spasm [15].
Prevedello and coworkers reported a shorter hospi-
talization time by high dose magnesium therapy in a
non-randomized study [53]. Muroi and coworkers
treated patients with a loading-dose of 16 mmol MgSO4
followed by a continuous infusion of 64 mmol/day. In 16
patients, magnesium infusions had to be discontinued
because of severe side effects, particularly hypotension,
although mean magnesium serum levels in these pa-
tients were only 1.40 mmol/l. The authors reported a
trend to better clinical outcome in magnesium treated
patients [21].
In a randomized, placebo-controlled multicenter study
conducted by van den Bergh et al. [17], patients received
a daily dose of 64 mmol MgSO4 for 14 days. The results
of this trial were promising as magnesium reduced the
risk of delayed cerebral ischemia by 34% and the risk for
poor outcome by 23%. Including 283 patients, however,
the study was still underpowered. In 2006, Stippler and
coworkers administered 50 mmol MgSO4 in 38 patients
and compared them to 38 matched controls in a
matched cohort study [54]. They found a reduced inci-
dence of secondary neurological deterioration and a ten-
dency to better neurological outcome. In a south-east
Asian/Australian trial, 327 patients were randomized to
receive a daily dose of 80 mmol/l MgSO4 or placebo.
The authors reported no significant benefit of
magnesium-treatment regarding clinical outcome after 6
months or clinical vasospasm [20]. The results of the lar-
gest clinical trial have just recently been published by
Mees and coworkers. In this European/South American
multicenter study, 1,204 patients with aneurysmal SAH
were enrolled and assigned to one of two study arms to
either receive 64 mmol MgSO4 per day or serve as con-
trols. The administration of MgSO4 did not improve
clinical outcome assessed 3 months after SAH [52].
The results of these clinical trials regarding the efficacy
of magnesium require a critical analysis. Except for the
very first clinical study by Luo et al. [50], who comparedTable 1 Clinical studies assessing the effects of intravenous m
Author Study setup Treatment arms and comedica
Wester et al., 1984
[40]
Tolerability study MgSO4 (15 mmol + 96 mmol/24
for 5 days)
Muir et al., 1995
[41]
Randomized,
placebo-controlled
MgSO4 (8 mmol + 65 mmol/kg
for 24 hours) vs. placebo
Muir et al., 1998
[16]
Randomized,
placebo-controlled
MgSO4 (8, 12 or 16 mmol +
65 mmol/kg for 24 hours) vs. pla
The IMAGES
investigators,
2004 [43]
Randomized,
placebo-controlled
MgSO4 (16 mmol + 65 mmol/kg
for 24 hours) vs. placebo
After promising experimental data and a trend to better outcome, a large multicen
magnesium in the over all study population. Solely the subgroup with lacunar infarmagnesium treatment to a true placebo group, all pa-
tients enrolled in these trials were co-treated with
nimodipine. Nimodipine, a pyrrolopyrimidine-type cal-
cium antagonist, has been intensively tested in various
clinical studies in the 1980s and 1990s. All trials but one
[55] failed to find a significant improvement of patient
outcome. Analyzing the pooled data for nimodipine tri-
als, a Cochrane review still revealed an advantage of
nimodipine treatment, so that this treatment is routinely
used in many centers. The Cochrane article concludes,
however, that the evidence for nimodipine “is not be-
yond any doubt” since the benefit of treatment is largely
determined by one trial [55,56]. Schmid-Elsaesser et al.
compared nimodipine treatment to magnesium treat-
ment and found no marked and significant difference in
the incidence of vasospasm and clinical outcome [51].
In our own placebo-controlled study 107 patients were
randomized to either receive a placebo infusion or to re-
ceive a variable dose of intravenous MgSO4 in order to
maintain serum concentrations of 2.0 – 2.5 mmol/l for 10
days or – if there was clinical, angiographic and/or ultra-
sonographic vasospasm – until the signs of vasospasm
had disappeared or to receive a placebo infusion [19]. The
patients were not treated with other calcium antagonists.
The incidence of ultrasonographic/angiographic vaso-
spasm and of secondary ischemic infarction was lower in
magnesium-treated patients. The improvement of out-
come and mortality did not reach the level of significance.
Perinatal asphyxia
Magnesium has for a long time been used for the treat-
ment of eclampsia [57]. For the treatment of eclamptic
seizures, it has been found to be more effective than
phenytoin and nimodipine [58,59]. Due to its reported
neuroprotective effect, observational studies have been
performed assessing the protective effect for the child.
In very low birth weight children, Nelson et al. [60] and
Schendel et al. [61] reported a lower incidence of cere-
bral palsy. Randomized trials for prenatal magnesium
administration were called for [62]. In large randomized
placebo-controlled trials, Marret et al. found a non-agnesium in ischemic stroke
tion Individuals Results
h 14 patients with
ischemic stroke
Magnesium-treatment well tolerated.
No information about outcome
60 patients with
ischemic stroke
Magnesium-treatment well tolerated,
tendency to better neurological outcome
cebo
25 patients with
ischemic stroke
All dose-regimens well tolerated.
No difference in outcome
2589 patients with
ischemic stroke
No over all reduction of death or disability
(primary end-point), trend to
benefit in lacunar stroke
ter clinical trial failed to demonstrate a beneficial effect of intravenous
ction showed a tendency to better recovery after magnesium medication.
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matter injury [63], Crowther et al. a significant improve-
ment of motor function [64] and Rouse et al. a reduced
rate of cerebral palsy [65]. In the MAGPIE trial, less chil-
dren had neurosensory deficits assessed by questionnaires,
however, without statistical significance [66] (Table 3a).
The results of these clinical trials were analyzed in a meta-
analysis that concluded that magnesium administration to
women at risk of preterm birth is neuroprotective for the
preterm fetus [67].
Several authors have assessed the neuroprotective effi-
cacy of magnesium administered after delivery to neonates
with asphyxia. Levene et al. [68] and Gathwala et al. [71]
assessed the safety of intravenous administrations of 250
mg/kg. Whereas Groenendaal and coworkers found no ef-
fect on pathological EEG patterns [69], Ishiba et al.
reported less pathological EEG- and CT-findings, a higher
rate of oral feeding and better short-term outcome [70].
Bath et al. [72] and Gathwala et al. [73] included develop-
mental and neurological outcome measures as endpoints
of their randomized placebo-controlled trials. Both groups
reported a reduction of neurological deficits and abnormal
CT-findings. However, both trials included only 40 pa-
tients and were underpowered to provide definitive evi-
dence for the effectiveness of postpartum administration
in perinatal asphyxia (Table 3b).
Conclusion and future prospects
Magnesium can be beneficial in cerebral ischemia. The
range of results suggests that its effect depends on theTable 2 Randomized clinical studies investigating the therape
vasospasm and secondary ischemic events and to improve ou
Author Study setup Treatment arms and comedicatio
Luo et al., 1996 [50] Randomized,
patient-blinded
MgSO4 (approx. 100 – 200 mmol
per day for 2 – 3 weeks) vs. placebo
Veyna et al., 2002 [18] Randomized,
patient-blinded
Nimodipine vs. nimodipine + MgSO
(25 mmol + 192 mmol/day for 10 d
Van den Bergh et al.,
2005 [17]
Randomized,
double-blinded
Nimodipine vs. nimodipine + MgSO
(64 mmol/day for 14 days)
Schmid-Elsaesser
et al., 2007 [51]
Randomized,
double-blinded
Nimodipine vs. MgSO4
(10mg/kg + 30mg/kg/day for 7 day
Muroi et al., 2008 [21] Randomized,
patient-blinded
Nimodipine vs. nimodipine + MgSO
(16 mmol + 64 mmol/24h, maximu
serum concentration 2.0 mmil/l)
Wong et al., 2010 [20] Randomized,
double blinded
Nimodipine vs. nimodipine + MgSO
(20 mmol + 80 mmol/day for 14 da
Westermaier et al.,
2010 [19]
Randomized,
double-blinded
MgSO4 (141 ± 51 mmol – target se
level 2.0 – 2.5 mmol/l) vs. placebo
Mees et al., 2012 [52] Randomized,
double-blinded
Nimodipine vs. nimodipine + MgSO
(64 mmol/day)
The results are not unequivocal. The beneficial effect might depend on the dose-retiming of treatment, route of administration, and co-
medication. Different forms of ischemia are likely to re-
quire different dose regimens. Magnesium levels in serum
and CSF are well controllable because they are easy to
measure and follow. Compared to other calcium antago-
nists, magnesium may be more suitable as a component of
a combination therapy [74].
Stroke
In spite of a reproducible neuroprotective effect in experi-
mental models of cerebral ischemia no randomized clin-
ical trial has, to date, confirmed the neuroprotective effect
in human stroke. The FAST-MAG trial, which is currently
being conducted, follows a novel concept as it is the first
clinical study which starts treatment before hospital ad-
mission. This trial conception considers that the delay
from the onset of ischemia to the start of infusion may
have been too long in the IMAGES trial to result in a
neuroprotective effect. Another interesting approach for
stroke therapy could be the combination of intravenous
magnesium with mild systemic hypothermia as recently
proposed by Zhu and Meloni after positive results in ex-
perimental studies [26,75].
Perinatal asphyxia
The administration of magnesium to women in preterm
labor has been studied in various randomized placebo-
controlled trials. A meta-analysis has found a benefit for
this treatment with respect to the neurological outcome
for the infant [67]. The effect of magnesium adminstrationutic effect of intravenous magnesium to prevent delayed
tcome after aneurysmal subarachnoid hemorrhage
n Individuals Results
52 patients Significant reduction of secondary
neurological deterioration, reduction
of delayed cerebral infarction
4
ays)
36 patients Safe use of magnesium. Non-significant
trend to improved clinical outcome
4 283 patients Reduction of delayed cerebral ischemia
and trend to better neurological outcome
s)
104 patients No significant difference between
magnesium and nimodipine
4
m
58 patients Trend to better clinical outcome after 3 and
12 months. Treatment was stopped in 16
patients due to hypotension, arrhythmias,
respiratory arrest and myocardial infarction
4
ys)
327 patients No reduction of secondary ischemia
or outcome
rum 107 patients Significant reduction of secondary infarction
and ultrasonographic/angiographic vasospasm.
Non-significant reduction of neurological
outcome and mortality
4 1207 patients No improvement of clinical outcome
gimen and comedication.
Table 3 Randomized clinical studies investigating the neuroprotective effect of magnesium administered before delivery to women at risk for preterm birth
(a) and administerd to children born at term after perinatal asphyxia (b)
Author Study setup Treatment arms and comedication Individuals Results
A
Schendel et al., 1996 [61] Observational Preterm administration for tocolysis.
Dose variable, observational study
1097 births with very low
birth-weight
Reduced risk for cerebral palsy and mental retardation
Crowther et al., 2003 [64] Randomized Preterm administration of 16 mmol MgSO4
followed by 4 mmol/h for 24 hours to
mother vs. placebo
1062 women in gest. week 30 or
less with birth planned within 24 hours
Lower rate of pediatric mortality and cerebral palsy in the
treatment group
Marret et al., 2007 [63] Randomized Preterm administration of 16 mmol
MgSO4 (4 g) single-dose over 30 minutes
573 women in gest. week 33 or less
with birth planned within 24 hours
Non-significant reduction of infant mortality and white matter
injury
Magpie Trial Follow-Up
Collaborative Group, 2007 [66]
Randomized Preterm administration of 16 mmol MgSO4
followed by 4 mmol/h for 24 hours to
mother vs. placebo
3283 children born before gest.
week 37
Non-significant reduction of disability after 18 months
Rouse et al., 2008 [65] Randomized Preterm administration of 24 mmol
MgSO4, followed by 8 mmol/h
2241 women in gest. week 24 – 32
with birth anticipated within 24 hours
Significant reduction of cerebral palsy
B
Levene et al., 1995 [68] open MgSO4 400 mg/kg vs. 250 mg/kg 15 full-term neonates with asphyxia 400 mg/kg: Serum level 3,6 mmol/l, profound hypotension
and respiratory depression
250 mg/kg: Serum level 2.42 mmol/kg, no effect on herat rate,
blood pressure and respiration
Groenendaal et al., 2002 [69] Randomized MgSO4 (250 mg/kg 30 min after birth
and 125 mg/kg after 24 and 48 hours
vs. placebo
22 full-term neonates with asphyxia No effect on pathological EEG patterns
Ichiba et al., 2002 [70] Randomized MgSO4 (3 × 250 mg/kg in 24-hour
intervals) vs. placebo
34 full-term neonates with asphyxia Less pathological CT- and abnormal EEG-findings. Higher rate of
oral feeding and good short-term outcome ( at 14 days of age)
in magnesium-treated children
Gathwala et al., 2006 [71] Randomized MgSO4 (250 mg/kg 30 min after birth
and 125 mg/kg after 24 and 48 hours
vs. placebo
40 full-term neonates with asphyxia Safe use of magnesium. No change in heart-rate,
respiratory rate of blood pressure
Bhat et al., 2009 [72] Randomized MgSO4 (3 × 250 mg/kg in 24-hour
intervals) vs. placebo
40 full-term neonates with asphyxia Less neurological abnormalities and pathological CT findings
Gethwala et al., 2010 [73] Randomized MgSO4 (250 mg/kg 30 min after birth and
125 mg/kg after 24 and 48 hours vs. placebo
40 full-term neonates with asphyxia Less EEG- and CT abnormalities and better short-term
outcome in magnesium-treated children
W
esterm
aier
et
al.Experim
ental&
TranslationalStroke
M
edicine
2013,5:6
Page
7
of
10
http://w
w
w
.etsm
journal.com
/content/5/1/6
Westermaier et al. Experimental & Translational Stroke Medicine 2013, 5:6 Page 8 of 10
http://www.etsmjournal.com/content/5/1/6to chidren born at term that suffered parinatal asphyxia is
not clear. Two randomized clinical studies have reported a
beneficial effect of magnesium therapy but were under-
powered. To date, no larger randomized trial has been
published.
Subarachnoid hemorrhage
Similar to the prophylactic preterm magnesium administra-
tion to infants at risk to suffer perinatal hypoxia,
neuroprotective drugs can be administered prior to delayed
vasospasm in subarachnoid hemorrhage. Large clinical tri-
als assessing the efficacy of magnesium in combination with
nimodipine, another calcium antagonist which is, in many
centers, used as a standard treatment for all patients, found
no additional, synergistic effect. Pharmacologically, the
co-administration of magnesium and other calcium-
antagonists is the attempt to enhance neuroprotection by
two similar substances. Thus, it is not surprising that
magnesium and nimodipine do not exert a synergistic
neuroprotective effect while specific side effects may be en-
hanced [21]. The results of Schmid-Elsaesser et al. showing
no significant difference between nimodipine treatment
and magnesium treatment, challenge the routine use of
nimodipine in aneurysmal SAH [51]. The comparison of
magnesium treatment to a true placebo group to prevent
secondary neurological deficits after SAH showed promis-
ing results [19,50] The bioavailability may still be improved
by a clinical dose-finding study. Even after continuous
high-dose treatment, however, CSF levels remain mark-
edly lower than serum levels [19] (Figure 2). For a
direct – topical - dilatory effect on subarachnoid ves-
sels, however, much higher concentrations are required
[76,77]. Those are not achievable by intravenous admin-
istration without serious side effects [12]. Intrathecal
administration of MgSO4 by a microcatheter placed dir-
ectly into the subarachnoid space has been examined by
Mori et al. in experimental models of SAH in rats and
dogs and has demonstrated a CBF-enhancing [78] and
spasmolytic effect [79]. First experiences in SAH pa-
tients suffering clinical deterioration due to cerebral
vasospasm showed an attenuation of cerebral vasocon-
striction [80]. Thus, an intracisternal therapy could be
an interesting and promising approach for a more effi-
cient therapy of delayed cerebral vasospasm.
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